Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024 08:05 ET | Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
thumbnail_Pan-Biome-logo.png
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
April 25, 2023 10:00 ET | Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
AMR Logo.png
Global Ulcerative Colitis Market Is Expected to Reach $10.8 Billion by 2030: Says AMR
July 03, 2022 20:30 ET | Allied Market Research
Portland, OR, July 03, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Ulcerative Colitis Market was estimated at $6.2 billion in 2020 and is...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma CEO Issues Letter to Shareholders
April 15, 2021 07:30 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma CEO Issues Letter to Shareholders
January 08, 2021 09:00 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces $8.0 Million Offerings
January 04, 2021 07:00 ET | AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
July 22, 2019 09:30 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...
Lyfebulb and UnitedH
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
July 26, 2018 09:00 ET | Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...
Lyfebulb and UnitedH
Lyfebulb and UnitedHealth Group Announce 11 Finalists for Their 2018 Innovation Challenge for Patient Entrepreneurs
June 28, 2018 09:00 ET | Lyfebulb
Challenge recognizes companies whose founders have been affected by inflammatory bowel disease Winners to receive monetary prizes for creative and effective solutions to address IBD MINNETONKA,...
IMC Logo.jpg
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
May 07, 2018 21:43 ET | Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...